Efficacy and safety of pegylated ifn alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C

Indian Journal of Gastroenterology

Volumn 29, Issue 2, 2010, Pages 62-65

  Sood, Ajit ^a   Sobti, Praveen ^a   Midha, Vandana ^a   Singla, Dinesh ^a   Kaur, Amarjeet ^a   Kaushal, Sandeep ^a   Sood, Neena ^a   Mittal, Rasham ^a   Puri, Sandeep ^a  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Blood transfusion; Hemolysis

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE; BETA THALASSEMIA; DRUG COMBINATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956635110     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: 10.1007/s12664-010-0014-3     Document Type: Article

References (19)

1. Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica 1994;79:353-5.
2. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol 1990;43: 638-40.
3. Marwaha RK, Bansal D, Sharma S, et al. Seroprevalence of hepatitis C and B virus in multiply transfused beta-thalassemics: results from a thalassemic day care unit in north India. Vox Sang 2003;85:119-20.
4. Jaiswal SP, Chitnis DS, Jain AK, Inamdar S, Porwal A, Jain SC. Prevalence of hepatitis viruses among multi-transfused homogenous thalassaemia patients. Hepatol Res 2001;19:247-53.
5. Agarwal MB, Malkan GH, Bhave AA, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics - Indian experience. J Assoc Physicians India 1993;41: 195-7.
6. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
7. Di Marco V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008;93:1243-6.
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
9. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
10. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
11. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432: 922-4.
12. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
13. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.
14. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109-12.
15. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002;117:755-8.
16. Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;98:850-5.
17. Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alfa-2a and ribavirin for the treatment of hepatitis C in patients with thalassaemia. Haematologica 2008;93:1247-51.
18. Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol 2008;23:203-7.
19. Tover JL, Buti M, Segarra A, Majo J, Esteban R. De novo nephrotic syndrome following pegylated interferon alfa 2b/ ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol 2008;40:539-41.